Heparin-induced thrombocytopenia with thrombosis;HEPARININDUZIERTE THROMBOPENIE UND THROMBOSE

Schweizerische Medizinische Wochenschrift

Volumn 126, Issue 12, 1996, Pages 483-488

  Stockli Th Ch ^a   Walther, A ^a   Gorres G ^a   Ritz, R ^a   Marbet, G A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; HEPARIN; PHENPROCOUMON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOSIS;

CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG COMBINATIONS; FRACTURES, BONE; HEPARIN; HEPARINOIDS; HEPARITIN SULFATE; HUMANS; MALE; MIDDLE AGED; PELVIC BONES; PULMONARY EMBOLISM; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0029972576     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Chong BH: Annotation: Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-439.
2. Greinacher A, Eichler P: Die Heparin-assoziierte Thrombocytopenie - Immunologische Aspekte. Hämostaseologie 1995; 15: 117-121.
3. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractioned heparin. N Engl J Med 1995; 332: 1330-1335.
4. Schmitt BP, Adelman B: Heparin-associated thrombocytopenia: A critical review and pooled analysis. Am J Med Sci 1993; 305: 208-215.
5. Stricker H, Lämmle B, Furlan M, Sulzer I: Heparin-dependent in vitro aggregation of normal platelets by plasma of a patient with heparin-induced skin necrosis: Specific diagnostic test for a rare side effect. Am J Med 1988; 85: 721-724.
6. Balestra B, Quadri P, Demarmels Biasiutti F, Furlan M et al.: Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites. Eur J Haematol 1994; 53: 61-63.
7. Amiral J, Bridey F, Wolf M, Moyer-Neumann C, Fressinaud E et al.: Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost 1995; 73: 21-28.
8. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard et al.: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994, 84: 3691-3699.
9. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995; 332: 1374-1376.
10. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
11. Boshkov LK, Warkentin TE, Hayward CPM, Kelton MA, Kelton JG: Heparin-induced thrombocytopenia and thrombosis; clinical and laboratory studies. Br J Haematol 1993; 84: 322-328.
12. Linde N, Tsakiris DA, Vogt A, Marbet GA: Heparininduzierte Thrombopenie. Perspektiven in einem therapeutischen Dilemma. Vasa 1991; 20: 157-163.
13. Vitoux JF, Mathieu JF, Roncato M, Fiesinger JN, Aiach M: Heparin-associated thrombocytopenia. Treatment with low molecular weight heparin. Thromb Haemost 1986; 55; 37-39.
14. Sheridan D, Carter C, Kelton JG: A diagnostic test for heparin-induced thrombocytopenia. Arch Intern Med 1985; 145; 1725-1726.
15. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C: A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-738.
16. Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E et al.: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96.
17. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C: Laboratory diagnosis of heparin-associated thrombocytopenia, comparison of platelet aggregation test, heparin-induced platelet activation (HIPA) test, and PF4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381-385.
18. Abu Rhama AF, Boland JP, Witsberger: Diagnostic and therapeutic strategies in white clot syndrome. Am J Surg 1991; 12: 175-179.
19. Teasdale SJ, Zulys VJ, Mycyk T, Baird RJ, Glynn M: Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 1989; 48: 712-713.
20. Taylor K, Southwick C: Anticoagulation and iloprost for heparin-induced thrombocytopenia. A case report. AANAJ 1991; 59: 432-436.
21. Cohen JI, Cooper MR, Greenberg CS: Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med 1985; 145: 1725-1726.
22. Prull A, Nechwatal R, Riedel H, Mäurer W: Therapie des Heparin-induzierten Thrombose-Thrombozytopenie-Syndroms mit Immunglobulinen. Dtsch Med Wochenschr 1992; 117: 1838-1842.
23. Magnani HN: Heparin-induced Thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554-561.
24. Chong BH: Heparin-induced thrombocytopenia. Aust N Z J Med 1992; 22: 145-152.
25. Meuleman DG: Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992; 22: 58-65.
26. Meuleman DG, Hobbelen PMJ, van Dedem G, Modker HC: A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity; a survey of its pharmacological properties in experimental animal models. Thromb Res 1982; 27: 353-356.
27. Nurmohamed MT, Fareed J, Hoppensteadt D, Walenga JM, ten Cate JW: Pharmacological and clinical studies with Lomaparan, a low molecular weight glycosaminoglycan. Semin Thromb Haemost 1991; 17 (Suppl. 2): 205-213.
28. De Valk HN, Banga JD, Wester JWJ, Brouwer CB, van Hessen MWJ et al.: Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995; 123: 1-9.
29. Lefkovits J, Topol E: Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-1536.
30. GUSTO IIa Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndroms. Circulation 1994; 90: 1631-1637.
31. Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R: Close P: Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72: 227-231.
32. Schiele F, Vuillemenot A, Kramarz Ph, Kieffer Y, Soria J et al.: A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 558-562.
33. Close P, Meyer D, Tsakiris DA, Graf P, Marbet GA: Effects of a recombinant hirudin infusion on ex vivo coagulation and platelet function tests in healthy volunteers [Abstract]. Eur Heart J 1990; 11: 385.
34. Hoet B, Tornai I, Arnout J, Close P, Vermylen J, Verstraete M: Open study of intravenous recombinant hirudin (CGP 39393) on platelet function and coagulation in healthy volunteers. Drug Invest 1994; 7: 127-133.
35. Close P, Bichler J, Kerry R, Ekman S, Bueller H er al.: Weak allergenicity of recombinant hirudin (Revasc®) in immunocompetent volunteers. Coronary Artery Dis 1994; 5: 943-949.
36. Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T et al.: Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Haematol 1995; 50 20-25.